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closure technique. Histologically, it was proved in these 
patients that the cancer affected only the external layer of 
the aortic wall. 
CT was a feasible means of judging whether malignant 
tumor had invaded the aorta by observing the motion of 
the tumors along the aortic wall. This method could be 
used for either purpose--to discriminate T4 tumors from 
others as a contraindication for resection or to devise a
strategy for concomitant resection of the aorta. Provided 
an invaded portion of the aorta, which is in contact with 
the immobile surface of a tumor, has been revealed clearly 
before the operation, a circulatory bypass and prosthesis 
required for resection and replacement of the wall can be 
arranged appropriately. In our seven cases, we took 
advantage of the new imaging modality in this way. 
In our series, one tumor in contact with the distal arch was 
erroneously judged to be invasive. The most likely reason for 
this misdiagnosis was that the tumor was located on the distal 
arch near the pulmonary hilus and thus showed barely 
detectable upward and ownward motion during breathing. 
For the same reason, a noninvasive tumor located on the 
diaphragm near the pulmonary ligament might be judged 
invasive by mistake. To avoid such misdiagnoses of pulmo- 
nary tumors located on the distal arch or diaphragm, the 
investigator should se the heartbeat mode as well as the 
breathing mode for more accurate valuation, rather than 
using the breathing mode alone. 
It is still difficult to discriminate between invasion and 
fibrous adhesion. We believe that cine CT should reveal 
malignant adhesion distinctly, because such invasion 
shows tougher attachment with less mobility than simple 
fibrous adhesion. A study including more patients will be 
required to address this issue. 
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APROTININ USE IN PATIENTS WITH DIALYSIS-DEPENDENT RENAL FAILURE UNDERGOING 
CARDIAC OPERATIONS 
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Thomas A. Molloy, MD, Jonathan G. Hill, MD, William B. Long, MD, Thomas R. Winkler, MD, and 
U. Scott Page, MD, Portland, Ore. 
It is occasionally necessary for patients with chronic 
renal failure (CRF) who are dependent on dialysis to 
undergo cardiac operations. Patients with CRF are at 
increased risk for excessive bleeding and often require 
substantial b ood product ransfusions in conjunction with 
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the surgical procedure. 13 Aprotinin, an inhibitor of fibri- 
nolysis with salutary effects on platelet function, decreases 
bleeding and blood product transfusion requirements 
when administered during cardiac operations, but pub- 
lished results of aprotinin use in patients with CRF is 
limited. 4-s In this report we describe seven patients de- 
pendent on dialysis who received aprotinin during cardiac 
procedures and compare them with nine patients with 
CRF who did not. 
Methods. Between February 1993 and May 1995, 16 
patients with dialysis-dependent CRF underwent cardiac 
operations done by our group. The patients required 
dialysis (peritoneal dialysis or hemodialysis) for CRF of 
various types. All patients underwent dialysis within the 
24-hour period before the operation. Standard blood 
conservation techniques were used in both groups, includ- 
ing tolerance of moderate to severe anemia, use of an 
intraoperative c ll scavenging device, and postoperative 
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Table I. Patient characteristics 
Aprotinin Control 
group group 
(n = 7) (n = 9) 
Age (yr) 60 + 15 60 +_ 13 
Weight (kg) 67 + 8 70 _+ 15 
Male gender 4/7 5/9 
CABG procedures 5/7 7/9 
Valve procedures 2/7 1/9 
Valve and CABG 0/7 1/9 
Use of intraoperative h mofiltration 4/7 5/7 
Numeric values are mean + standard eviation. There were no 
significant differences between the two groups. CABG, Coronary artery 
bypass graft. 
autotransfusion of shed mediastinal blood. The control 
group patients were not matched; aprotinin administra- 
tion was open label and not randomized. Patient charac- 
teristics are summarized in Table I. 
In the aprotinin-treated group, four of the patients had 
elective operations and three urgent operations because 
of unstable angina symptoms. Two patients were receiving 
continuous intravenous heparin when the operation was 
begun and two patients had received aspirin within 24 
hours of the operation. In the control group none was 
treated with aprotinin, one received intraoperative amin- 
ocaproic acid, and one procedure was performed with 
heparin-coated eXtracorporeal circulation (ECC) tubing 
and oxygenator. Five of these operations were performed 
on an urgent basis and four were lective. One patient was 
receiving intravenous heparin just before the operation 
and one patient had received aspirin within 3 days of the 
operation. One operation was a second procedure. 
Aprotinin (Bayer Corporation, Pharmaceutical Divi- 
sion, West Haven, Conn.) was administered as follows: 
280 mg loading dose over 20 minutes before beginning 
ECC, 280 mg added to the ECC prime solution, and a 
continuous infusion of 70 mg/hr during the operation. 
Standard anesthetic technique was used and the ECC 
circuit used a centrifugal pump and membrane oxygen- 
ator. Diastolic arrest of the heart was induced with cold 
blood hyperkalemic (20 mEq/L) cardioplegic solution, 
and maintenance doses of low-potassium (4 mEq/L) car- 
dioplegic solution were administered uring the cross- 
clamp period. Moderate systemic hypothermia (28 ° to 
32 ° C) was used in all patients. In control patients antico- 
agulation for ECC was achieved by standard techniques to 
maintain the kaolin activated clotting time (ACT) above 
480 seconds during the period of ECC. For the patient in 
whom heparin-bonded circuitry was used, the ACT level 
was maintained at 200 to 300 seconds. Anticoagulation for 
the aprotinin-treated group was accomplished by use of an 
ACT-directed fixed-dose heparin regimen. For this pur- 
pose, the patient received a loading dose of 450 units of 
heparin per kilogram to achieve a prebypass kaolin ACT 
of more than 600 seconds. Additionally, 10,000 units of 
heparin was added to the ECC circuit prime solution and 
the patient received 100 units of heparin per kilogram 
every 60 minutes during bypass (irrespective of the most 
Table II. Chest tube drainage, transfusions, and 
complicat ions 
Aprotinin Control p 
(n = 7) (n = 9) Value 
Twelve-hour drainage (ml) 315 +- 103 1096 + 561 0.001 
Total drainage (mI) 486 _+ 159 1271 _+ 710 0.060 
Mean No. of total blood 3.7 _+ 4 29.0 _+ 32 0.041 
product exposures per 
patient 
Mean No. of RBC units 2.0 -+ 2 6.0 + 7 0.315 
transfused 
Mean No. of platelet units 1.7 -+ 3 14.6 _+ 16 0.011 
transfused 
Mean No. of plasma units 0 4.8 -+ 7 0.011 
transfused 
Mean No. of cryoprecipi- 0 3.6 -+ 7 0.475 
tate units transfused 
Reoperations for bleeding 0/7 2/9 NC 
Deaths 0/7 1/9 NC 
Preop. hematocrit value 33.1 35.4 NC 
(~) 
Postop. hematocrit value 32.7 30.3 NC 
(%) 
RBC, Red blood ceil; NC, not calculated. 
recent ACT determination). The protamine dose was 0.75 
mg/100 total heparin units administered. 
Blood products were transfused at the discretion of 
the operating surgeon and no specific criteria were 
used. In general, however, red blood cells were transfused 
for a hematocrit level of less than 18% during ECC and 
21% after the operation, with additional blood product 
transfusions given when clinically indicated. All p values 
were computed by means of Fisher's exact test. In Table 
II, a median test was applied; all variables were first 
categorized as to whether the value was above the sample 
mean. 
Results. Characteristics of the patients in the two 
groups were similar (Table I). Table II summarizes the 
volumes of chest tube drainage and blood product rans- 
fusion requirements. Chest tube drainage in the first 
12 hours and total chest tube drainage volumes were 
smaller in the patients treated with aprotinin, although the 
latter difference did not reach statistical significance. 
Substantially fewer total blood product ransfusions were 
required by the patients who received aprotinin. The 
mean number of red blood cells transfused to them was 
one third the number transfused to the control patients, 
but this difference did not reach statistical significance, 
presumably because of the small number of patients 
compared. 
Two control group patients required exploration be- 
cause of excessive postoperative bleeding as compared 
with none of the patients receiving aprotinin. Both pa- 
tients had diffuse bleeding. No strokes or myocardial 
infarctions (assessed by electrocardiograms and postoper- 
ative creatine kinase MB levels) occurred in any of the 
patients. One 72-year-old patient from the control group 
died of coagulopathy (necessitating exploration for bleed- 
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ing) and cardiac and liver failure after a second coronary 
bypass graft procedure. Severe gastrointestinal hemor- 
rhage developed on the fifth postoperative day in one 
patient treated with aprotinin, necessitating transfusions 
of red blood cells (2 units) and platelets (6 units). These 
transfusions were included in the calculations of the 
means shown in Table II. Telephone follow-up (mean 15 
months after the operation) of the aprotinin-treated 
group found five alive and angina free (two on kidney 
transplant waiting lists); one 85-year-old patient had died 
of unknown causes and one 58-year-old patient had died 
of "atherosclerosis" 4 and 14 months, respectively, after 
their operations. 
Comment. Abnormalities of the hemostatic system in 
patients with CRF are widely recognized and appear to be 
multifactorial in origin. 7 Multiple reports indicate that 
cardiac operations may be performed successfully in pa- 
tients with CRF, although complication rates are higher 
and the overall mortality is estimated to be 9%. 1 In 
publications that provide this information, the mean num- 
ber of blood product ransfusions per patient with CRF 
undergoing cardiac procedures ranged from 8 to 20 units 
per patient. 1-3 This is considerably greater than the aver- 
age of 4 units per patient who received aprotinin during 
the operations as described in this report. 
The choice of aprotinin dose regimen for our patients 
was based on reported results available at the time of their 
operations. Subsequently, evidence has emerged indicat- 
ing efficacy of smaller aprotinin doses. 6 In patients with 
normal renal function, aprotinin is excreted by the kid- 
neys. In patients with CRF the route of elimination is not 
known, although some proportion may be cleared by 
dialysis. Because arly renal aprotinin elimination cannot 
occur in patients with CRF, a lower dose should likely be 
effective in these patients (at a lower cost). 
This is a retrospective r port of two small groups of 
patients with dialysis-dependent CRF who were operated 
on by one group of surgeons, and it is subject o limita- 
tions of such reports. The patients were not randomized 
with regard to aprotinin treatment, blinded conditions 
were not used, and strict transfusion criteria were not 
applied. It is therefore an observational report rather than 
an investigation rigorously comparing two treatment mo- 
dalities. Nevertheless, in our experience with seven pa- 
tients with dialysis-dependent CRF undergoing cardiac 
operations, high-dose aprotinin administration was asso- 
ciated with reductions in bleeding and homologous blood 
product ransfusions, and no complications related to the 
use of the drug were identified. For these reasons, it is our 
current recommendation that aprotinin be used in this 
group of patients who are at high risk for perioperative 
hemorrhagic problems. On the basis of recently published 
results, the use of a smaller aprotinin dose should be 
considered. 
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